Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:42:32.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    Locations now include Massachusetts; HHS Vulnerability Disclosure and Massachusetts Locations sections were removed.
    Difference
    0.2%
    Check dated 2025-12-23T10:11:36.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Revision: v3.3.2 is now shown, replacing the previous v3.3.1. No other study content or functionality appears to be affected.
    Difference
    0.1%
    Check dated 2025-12-01T17:46:49.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    Minor wording updates to the Publications section indicate that items are automatically filled from PubMed, and revision numbers have been updated to v3.3.1 and v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T14:47:55.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    Removed the banner that informed users about a lapse in government funding and NIH operating status. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T06:55:30.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    Enrollment updated to 90 participants with a Primary Completion date of 2018-10-11 and a Study Completion date of 2023-09-05.
    Difference
    0.5%
    Check dated 2025-11-03T01:19:15.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.